1. Renin inhibition

   • Hollis D. Kleinert

   Review Pages: 645 - 655

2. Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: Focus on felodipine

   • William C. Little
   • Che-Ping Cheng
   • Margareta Nordlander

   Review Pages: 657 - 663

3. Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): Potent dose-dependent inhibition of platelet function

   • Shoumo Bhattacharya
   • Robert Jordan
   • Avijit Lahiri

   Platelet Function Pages: 665 - 675

4. Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs

   • Adrian S. Dobs
   • Mukesh Prasad
   • Donald R. Hoover

   Lipid-Lowering Drugs Pages: 677 - 684

5. Pharmacodynamics and pharmacokinetics of clentiazem and diltiazem in closed-chest anesthetized dogs

   • Sylvie Giasson
   • Denis Garceau
   • Louis Dumont

   Calcium Antagonists Pages: 685 - 692

6. Angiotensin II receptor antagonists in heart failure: Rationale and design of the evaluation of losartan in the elderly (ELITE) trial

   • Bertram Pitt
   • Paul Chang
   • Pieter B. M. WW. M. Timmermans

   Heart Failure Pages: 693 - 700

7. Experimental rat model representing both acute and chronic heart failure related to autoimmune myocarditis

   • Sen Koyama
   • Makoto Kodama
   • Akira Shibata

   Heart Failure Pages: 701 - 707

8. Electrophysiological evaluation of the sodium-channel blocker carbamazepine in healthy human subjects

   • Göran Kennebäck
   • Lennart Bergfeldt
   • Torbjörn Tomson

   Antiarrhythmics Pages: 709 - 714

9. Rate-dependent anisotropic conduction property in the epicardial border zone of canine myocardial infarcts and its modification by moricizine

   • Noriyuki Tsutsumi
   • Hideo Mitamura
   • Satoshi Ogawa

   Antiarrhythmics Pages: 715 - 722

10. Digoxin and increased mortality among patients recovering from acute myocardial infarction: Importance of digoxin dose

    • Jonathan Leor
    • Uri Goldbourt
    • the SPRINT Study Group

    Digoxin Pages: 723 - 729

11. Referee awards

    Acknowledgments Pages: 731 - 731